ORCID Profile
0000-0002-5521-6277
Current Organisation
The University of Auckland
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: CSIRO Publishing
Date: 2014
DOI: 10.1071/CH13452
Abstract: We report the multistep synthesis and polymerisation of a novel aniline derivative with a pendant α-d-mannose substituent. The α-D-mannose functionality was successfully introduced before polymerisation via copper-catalysed azide alkyne click chemistry and the resulting monomer was polymerised using general oxidative polymerisation conditions, producing a water soluble mannosylated polyaniline. The polymer was characterised by several techniques and compared with standard polyaniline. The selective binding of the polymer to Concanavalin A (ConA) was successfully demonstrated by the precipitation of polymer–ConA aggregates. Potential applications of these novel polyaniline glycopolymers could include the development of electroactive biomaterials with the ability to bind mannose receptors, or as sensors for proteins or microbes.
Publisher: Royal Society of Chemistry (RSC)
Date: 2020
DOI: 10.1039/C9PY01419E
Abstract: For the first time, we report 3D printing of RAFT-based formulations to fabricate functional objects in a layer-by-layer fashion.
Publisher: Wiley
Date: 09-12-2019
Publisher: Springer Science and Business Media LLC
Date: 30-07-2018
DOI: 10.1007/S12035-018-1251-1
Abstract: Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD and in genetic prion diseases associated with the three most common mutations E200K, V210I (associated with genetic CJD) and D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions.
Publisher: Wiley
Date: 02-12-2019
Publisher: American Chemical Society (ACS)
Date: 10-11-2017
DOI: 10.1021/ACS.BIOMAC.7B01245
Abstract: Six guanidine functionalized aliphatic biodegradable polycarbonates with varying molecular weights and charge densities were synthesized via postsynthesis modification of alkyne containing polycarbonates using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. The concept of passive diluting group was to modify the cationic charge density of the polycarbonate without changing its hydrophilicity. Within the molecular weight range from 8000 to 30000 g mol
Publisher: American Chemical Society (ACS)
Date: 16-07-2020
Publisher: American Chemical Society (ACS)
Date: 20-02-2019
Publisher: American Chemical Society (ACS)
Date: 25-07-2022
Publisher: CSIRO Publishing
Date: 2015
DOI: 10.1071/CH14513
Abstract: The objective of this research was to develop novel phosphonate-containing polymers as they remain a relatively under researched area of polymer chemistry. Herein, we report the synthesis and characterization of 2-(1-(2-(diethoxyphosphoryl)ethyl)-1H-1,2,3-triazol-4-yl)ethyl acrylate (M1) and diethyl (2-(4-(2-acrylamidoethyl)-1H-1,2,3-triazol-1-yl)ethyl)phosphonate (M2) monomers using the copper-catalyzed azide–alkyne cycloaddition (CuAAC) ‘click’ reaction, and their subsequent polymerization via both uncontrolled and reversible addition–fragmentation chain transfer (RAFT) polymerization techniques yielding phosphonate polymers (P1–P4).
Publisher: Wiley
Date: 27-05-2020
Publisher: Wiley
Date: 15-11-2019
Publisher: Wiley
Date: 04-03-2015
DOI: 10.1002/POLB.23689
Publisher: Wiley
Date: 09-12-2019
Abstract: Reversible addition-fragmentation chain-transfer (RAFT) polymerization is a valuable tool for synthesizing macromolecules with controlled topologies and erse chemical functionalities. However, the application of RAFT polymerization to additive-manufacturing processes has been prevented due to the slow polymerization rates of typical systems. In this work, we developed and optimized a rapid visible (green) light mediated RAFT polymerization process and applied it to an open-air 3D printing system. The reaction components are non-toxic, metal free and environmentally friendly, which tailors these systems toward biomaterial fabrication. The inclusion of RAFT agent in the photosensitive resin provided control over the mechanical properties of 3D printed materials and allowed these materials to be post-functionalized after 3D printing. Additionally, photoinduced spatiotemporal control of the network structure provided a one-pass approach to 4D printed materials. This RAFT-mediated 3D and 4D printing process should provide access to a range of new functional and stimuli-responsive materials.
Publisher: American Chemical Society (ACS)
Date: 24-01-2020
Publisher: Royal Society of Chemistry (RSC)
Date: 2013
DOI: 10.1039/C3RA42781A
Publisher: American Chemical Society (ACS)
Date: 24-03-2017
Publisher: American Chemical Society (ACS)
Date: 17-06-2019
Publisher: American Chemical Society (ACS)
Date: 19-05-2021
Publisher: Oxford University Press (OUP)
Date: 02-2022
Abstract: Genetic prion diseases are a rare and erse group of fatal neurodegenerative disorders caused by pathogenic sequence variations in the prion protein gene, PRNP. Data on CSF biomarkers in patients with genetic prion diseases are limited and conflicting results have been reported for unclear reasons. Here, we aimed to analyse the diagnostic accuracy of CSF biomarkers currently used in prion clinical diagnosis in 302 symptomatic genetic prion disease cases from 11 prion diagnostic centres, encompassing a total of 36 different pathogenic sequence variations within the open reading frame of PRNP. CSF s les were assessed for the surrogate markers of neurodegeneration, 14-3-3 protein (14-3-3), total-tau protein (t-tau) and α-synuclein and for prion seeding activity through the real-time quaking-induced conversion assay. Biomarker results were compared with those obtained in healthy and neurological controls. For the most prevalent PRNP pathogenic sequence variations, biomarker accuracy and associations between biomarkers, demographic and genetic determinants were assessed. Additionally, the prognostic value of biomarkers for predicting total disease duration from symptom onset to death was investigated. High sensitivity of the four biomarkers was detected for genetic Creutzfeldt–Jakob disease associated with the E200K and V210I mutations, but low sensitivity was observed for mutations associated with Gerstmann–Sträussler–Scheinker syndrome and fatal familial insomnia. All biomarkers showed good to excellent specificity using the standard cut-offs often used for sporadic Creutzfeldt–Jakob disease. In genetic prion diseases related to octapeptide repeat insertions, the biomarker sensitivity correlated with the number of repeats. New genetic prion disease-specific cut-offs for 14-3-3, t-tau and α-synuclein were calculated. Disease duration in genetic Creutzfeldt–Jakob disease-E200K, Gerstmann–Sträussler–Scheinker-P102L and fatal familial insomnia was highly dependent on PRNP codon 129 MV polymorphism and was significantly associated with biomarker levels. In a large cohort of genetic prion diseases, the simultaneous analysis of CSF prion disease biomarkers allowed the determination of new mutation-specific cut-offs improving the discrimination of genetic prion disease cases and unveiled genetic prion disease-specific associations with disease duration.
No related grants have been discovered for Jianyong Jin.